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SUMM A R Y
An infant born to a woman with human immunodeficiency virus type 1 (HIV-1) 
infection began receiving antiretroviral therapy (ART) 30 hours after birth owing to 
high-risk exposure. ART was continued when detection of HIV-1 DNA and RNA on 
repeat testing met the standard diagnostic criteria for infection. After therapy was 
discontinued (when the child was 18 months of age), levels of plasma HIV-1 RNA, 
proviral DNA in peripheral-blood mononuclear cells, and HIV-1 antibodies, as assessed 
by means of clinical assays, remained undetectable in the child through 30 months 
of age. This case suggests that very early ART in infants may alter the establishment 
and long-term persistence of HIV-1 infection.
Nearly 70 million persons have acquired HIV-1 infection since the epidemic was recognized,1 but a “cure” has been documented in one person, known as “the Berlin Patient.” 2,3 A cure for HIV-1 infection oc-
curred in this person after he underwent treatment for acute myelogenous leukemia 
with total ablative chemotherapy, radiation therapy, and stem-cell transplantation 
with donor cells homozygous for chemokine receptor 5 (CCR5) delta32, with as-
sociated graft-versus-host disease. The case of the Berlin Patient shows that long-
lived, replication-competent HIV-1 reservoirs can be reduced or cleared sufficiently 
to permit the discontinuation of ART without subsequent viral rebound. We report 
data from a 30-month-old child who had met the standard diagnostic criteria for 
HIV-1 infection and who now has undetectable levels of circulating HIV-1 RNA, 
proviral DNA, and HIV-1 antibodies, as assessed by means of clinical assays, after 
combination ART was administered between 30 hours and 18 months of age.
C A SE R EPORT
An infant was born by spontaneous vaginal delivery at 35 weeks of gestation to a 
woman who had received no prenatal care. Rapid HIV-1 testing in the mother was 
positive during labor. Delivery occurred before antiretroviral prophylaxis was ad-
ministered. Maternal HIV-1 infection was confirmed by means of Western blot 
testing. The mother’s plasma viral load, CD4+ T-cell count, and HIV-1 subtype and 
genotype are summarized in Table 1.
ART was initiated in the infant at 30 hours of age. A three-drug regimen of 
zidovudine (at a dose of 2 mg per kilogram of body weight every 6 hours), lami-
vudine (at a dose of 4 mg per kilogram twice daily), and nevirapine (at a dose of 
2 mg per kilogram twice daily) was selected to provide prophylaxis for high-risk 
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HIV-1 exposure and to minimize the likelihood 
of generating resistant viral variants in the event 
that the infant had been infected in utero.
The detection of HIV-1 DNA in peripheral-
blood mononuclear cells (PBMCs) in blood ob-
tained at 30 hours of age (Table 1) and the detec-
tion of HIV-1 RNA (19,812 copies per milliliter) 
in a separate blood sample collected at 31 hours 
of age met the standard diagnostic criteria for 
HIV-1 infection in the infant.4 Therefore, ART 
was continued. When the infant was 1 week of 
age, ritonavir-boosted lopinavir was substituted 
for nevirapine to reduce the risk of antiretroviral 
drug resistance in case there was incomplete 
adherence to the prescribed ART. The decision 
to implement this regimen preceded warnings 
from the Food and Drug Administration against 
the use of ritonavir-boosted lopinavir in infants 
younger than 14 days of age.5
While the infant was receiving ART, the HIV-
1 RNA level remained detectable in plasma at 
three additional time points (2617 copies per 
milliliter at 6 days of age, 516 copies per milli-
liter at 11 days of age, and 265 copies per milli-
liter at 19 days of age) (Table 1 and Fig. 1) before 
declining below assay-detection limits when the 
infant was 29 days of age. The decline in the 
plasma viral load was biphasic and similar to 
Table 1. Laboratory Testing and Antiretroviral Therapy Received by Mother and Child.*
Test Result Antiretroviral Therapy
Mother
Rapid HIV antibody, at delivery Positive None
HIV ELISA and confirmatory Western 
blot, at 24 hr
Positive None
Viral load, at 24 hr 2423 copies/ml None
CD4+ T-cell count, at 14 days 644 cells/mm3 None
HIV-1 genotype and subtype, at 14 days Wild-type, subtype B None
CD4+ T-cell count, at 26 mo 513 cells/mm3 None
HIV-1 viral load, at 26 mo 6763 copies/ml None
HLA typing, at 26 mo A3, A23, B7, B14, Cw7, and Cw8 None
Mutation status in CCR5 delta32, 
at 26 mo
Nonmutated None
Frequency of infected cells, at 28 mo 137 IUPM None
Child
HIV-1 DNA, at 30 hr Positive Zidovudine
HIV-1 RNA, at 31 hr 19,812 copies/ml Zidovudine, lamivudine, and nevirapine
HIV-1 RNA, at 6 days 2617 copies/ml Zidovudine, lamivudine, and nevirapine
HIV-1 RNA, at 11 days 516 copies/ml Zidovudine, lamivudine, and ritonavir-
boosted lopinavir
HIV-1 RNA, at 19 days 265 copies/ml Zidovudine, lamivudine, and ritonavir-
boosted lopinavir
HIV-1 RNA, at 29 days <48 copies/ml Zidovudine, lamivudine, and ritonavir-
boosted lopinavir
CD4+ T-cell percentage, at 8 days 69% Zidovudine, lamivudine, and ritonavir-
boosted lopinavir
HLA typing, at 26 mo A3, A68, B7, B39, and Cw7 None
Mutation status in CCR5 delta32,  
at 26 mo
Nonmutated None
* All specified time points are post partum. CCR5 denotes chemokine receptor 5 gene, ELISA enzyme-linked immuno-
sorbent assay, HIV human immunodeficiency virus, HIV-1 HIV type 1, and IUPM infectious units per 1 million resting 
CD4+ T cells.
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that described previously in HIV-1 infected in-
fants7,8 and adults receiving ART.9
In the infant’s first year of life, during which 
the infant was not breast-fed, adherence to ART 
was assessed as adequate on the basis of phar-
macy records indicating timely prescription re-
fills, undetectable plasma viral loads, and red-
cell macrocytosis during zidovudine treatment. 
Concern about medication adherence was raised 
when the child was 18 months of age, when the 
red-cell mean corpuscular volume, which had 
been more than 101 femtoliters (fl) before 15 
months of age, decreased to 95 fl, although the 
plasma level of HIV-1 RNA remained undetect-
able (<20 copies per milliliter).
Between 18 and 23 months of age, the child 
missed several clinic visits. When the child was 
brought back for care at 23 months of age, the 
mother reported that ART had been discontin-
ued when the child was 18 months of age, al-
though pharmacy records indicated that the 
prescription was last refilled when the child was 
15 months of age. In blood samples obtained at 
23 and 24 months of age, the plasma level of 
HIV-1 RNA was undetectable. A repeat HIV-1 
DNA polymerase-chain-reaction (PCR) test at 24 
months of age was negative, as was an HIV-1 
antibody test.
At the time of this report, the child had not 
received any antiretroviral drugs through 30 
months of age, and the plasma level of HIV-1 
RNA had remained undetectable by routine 
clinical assays (Fig. 1). Circulating HIV-1 anti-
bodies have also not been detected (Fig. S1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The CD4+ 
T-cell percentages were within or exceeded the 
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Figure 1. Detection of Human Immunodeficiency Virus 
Type 1 (HIV-1) Infection in the Child.
Panel A shows HIV-1 RNA levels indicating confirmed 
HIV-1 infection, with positive values for HIV-1 RNA in 
plasma at four time points before and after the initia-
tion of antiretroviral therapy (ART). The decline in the 
viral load was biphasic, which is typically seen during 
effective ART. Panel B shows HIV-1 RNA levels indicat-
ing sustained control of HIV-1 replication during ART 
and after the discontinuation of therapy. The solid ar-
row indicates the last time that prescriptions for ART 
were filled (at 15 months of age, according to pharma-
cy records), and the dashed arrow the time of the last 
administration of ART (at 18 months of age, according 
to maternal report). In both Panel A and Panel B, solid 
circles indicate detectable HIV-1 RNA, and open circles 
undetectable HIV-1 RNA; the shaded area indicates the 
limit of detection of the plasma viral-load assay. Panel C 
shows the percentage of CD4+ T cells from the child’s 
birth until 30 months of age. The shaded area indicates 
the CD4+ T-cell percentage in the normal range (10th 
to 90th percentiles); fluctuations in the normal range 
are due to age-related changes.6 3TC denotes lamivu-
dine, AZT zidovudine, and NVP nevirapine.
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normal range for age at all time points tested 
(Fig. 1C).6 Growth and development have been 
normal. Detailed virologic and immunologic 
studies were performed to characterize the per-
sistence of HIV-1 infection in this unique case.
ME THODS
DIAGNOSIS AND MONITORING OF HIV-1 INFECTION
We performed standard HIV-1 DNA PCR testing 
with the use of the Amplicor HIV-1 DNA assay 
(Roche Molecular Systems) and HIV-1 RNA test-
ing with the use of the COBAS AmpliPrep/COBAS 
Taqman HIV-1 test (Roche Molecular Systems). 
The testing was performed at laboratories that 
were certified by the Clinical Laboratory Im-
provement Amendments (CLIA) program: Focus 
Diagnostics and Mayo Medical Laboratories for 
HIV-1 DNA testing and University of Mississippi 
Medical Center for HIV-1 RNA testing. The COBAS 
AmpliPrep/COBAS Taqman HIV-1 test, version 
1.0 (limit of detection [LOD], <48 copies per milli-
liter), was used for samples tested before the 
child was 5 months of age, and version 2.0 (LOD, 
<20 copies per milliliter) was used thereafter. 
CD4+ T cells were enumerated with the use of 
flow cytometry.
HIV-1–SPECIFIC IMMUNE RESPONSES, HLA TYPING, 
AND CCR5 GENOTYPING
HIV-1 antibody testing was performed with the 
use of enzyme-linked immunosorbent assays and 
Western blot testing (Cambridge Biotech HIV-1 
Western Blot Kit, Maxim Biomedical). Intra-
cellular cytokine assays were used to detect 
HIV-1–specific CD4+ and CD8+ T-cell responses 
to pooled gag and nef peptides. Cell-surface 
markers for immune activation were evaluated 
with the use of f low cytometry. HLA typing was 
performed with the use of the Bio-Rad HLA 
 Sequence Specific Primers kit (Biotest). CCR5 
genotyping for the delta32 mutation was per-
formed with the use of previously published 
methods.10
VIROLOGIC ASSAYS TO QUANTIFY HIV-1 
PERSISTENCE
The presence of replication-competent virus in 
maternal and infant samples was determined 
with the use of a limiting-dilution quantitative 
coculture assay of PBMCs enriched for resting 
CD4+ T cells.11 Replication efficiencies of the 
maternal isolates were compared with an HIV-1 
reference strain to assess viral fitness.12 Low-
level viremia was quantified by means of two as-
says: a single-copy viral-load assay13 and a modi-
fied COBAS AmpliPrep/COBAS Taqman HIV-1 
test, version 2.0.14 We tested for the presence of 
proviral DNA and 2–long terminal repeat circles 
in PBMCs, resting CD4+ T cells, and cellular 
fractions enriched for monocytes and activated 
cells with the use of a highly sensitive droplet 
digital PCR assay (LOD, <3 copies per 106 cells).15
R ESULT S
IMMUNOLOGIC AND VIROLOGIC TESTING 
Maternal HIV-1 antibody tests that were per-
formed 24 months after delivery showed reactiv-
ity to all nine HIV-1 proteins tested (Fig. S1 in the 
Supplementary Appendix). The mother did not 
begin receiving ART. At 26 months after delivery, 
the maternal HIV-1 RNA level was 6763 copies 
per milliliter. At 28 months after delivery, fully 
replication-competent virus was recovered from 
a maternal blood sample at a frequency of 137 
infectious units per million resting CD4+ T cells; 
viral isolates showed replication kinetics similar 
to the IIIB laboratory strain of HIV-1. HLA typing 
of the mother and infant revealed shared haplo-
types, confirming their relationship (Table 1). 
Neither the mother nor the infant had HLA class 
I alleles that are associated with spontaneous 
control of HIV-1 infection (HLA-B27 or HLA-
B*57); both were nonmutated for CCR5.
HIV-1 antibodies were not detected in the 
child at 24, 26, and 28 months of age (Fig. S1 in 
the Supplementary Appendix). T-cell activation 
markers were within normal limits at 24 and 30 
months of age (at 24 months, 2% of the T cells 
were CD4+/HLA-DR+; at 30 months, 6% of the 
T cells were CD8+/CD38+/HLA-DR+). HIV-1–spe-
cific CD4+ and CD8+ T-cell responses were not 
detected at 28 months of age.
Ultrasensitive virologic tests were performed 
to evaluate the persistence of HIV-1 infection in 
the child (Table 2). Viral RNA was detected at a 
single-copy level in plasma obtained at 24 
months of age but was not detected at 26 
months of age. HIV-1 proviral DNA was detected 
near the limits of detection at both time points 
but not in resting CD4+ T cells (Table 2). A cul-
ture of 22 million resting CD4+ T cells obtained 
at 24 months of age, during a period in which 
the child was not receiving ART, did not yield 
replication-competent HIV-1.
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DISCUSSION
We report data from a 30-month-old child who 
met the standard diagnostic criteria for HIV-1 in-
fection, received combination ART between 30 
hours and 18 months of age, and subsequently 
had controlled HIV-1 viremia for 12 months 
while not receiving ART. The absence of rebound 
viremia, the undetectable replication-competent 
virus, the almost-complete disappearance of cell-
associated HIV-1 DNA, and the absence of HIV-1–
specific immune responses while the child was 
not receiving ART suggest that replication-compe-
tent HIV-1 reservoirs may not have been established 
or were markedly abated, if not extinguished.16
Rare cases of transient HIV infection in in-
fants have been reported, on the basis of inter-
mittent detection of HIV-1 p24 antigen or DNA 
in peripheral blood.17-20 One cohort study showed 
that 6.4% of 188 infants had one or more posi-
tive tests for HIV that were followed by negative 
tests.20 However, forensic and phylogenetic stud-
ies could not rule out laboratory contamination 
or sample mislabeling in reported cases of spon-
taneous HIV-1 clearance.21 In the present case 
report, the five positive tests indicating HIV-1 
infection were performed in CLIA-certified labo-
ratories with the use of separate blood speci-
mens and standard clinical-assay protocols. 
Under this scenario, repeated sample mix-up or 
contamination was unlikely. Unfortunately, clin-
ical specimens are not routinely saved, which 
precluded further assessment of specimens from 
those time points.
The current standard definition of HIV-1 in-
fection in an infant requires the detection of 
HIV-1 nucleic acids in at least two separate 
clinical samples.4 An infant in whom HIV-1 DNA 
is detected in blood obtained within the first 48 
hours after birth is considered to have acquired 
the infection in utero.22 The detection of HIV-1 
proviral DNA in this infant’s peripheral blood at 
Table 2. Specialized Studies to Assess Persistence of HIV-1 Infection in the Child.*
Sample Type Quantity Cells Tested
no. of cells or 
plasma volume
no. of positive 
replicates/ 
no. of wells
Total proviral DNA
PBMCs
At 24 mo <2.7 copies/106 cells 122,000 0/2
At 26 mo 4.2 copies/106 cells† 113,000 1/6
Resting CD4+ T cells
At 24 mo <3.5 copies/106 cells 96,500 0/3
At 26 mo <2.5 copies/106 cells 134,000 0/6
PBMCs enriched for activated CD4+ T cells
At 24 mo <2.2 copies/106 cells 154,000 0/6
At 26 mo <2.6 copies/106 cells 130,000 0/6
Monocyte-derived adherent cells
At 24 mo 37.6 copies/106 cells‡ 14,300 1/3
At 26 mo <11.5 copies/106 cells 29,000 0/6
Residual viremia in plasma
At 24 mo 1 copy/ml 4 ml 3/3
At 26 mo <2 copies/ml 4 ml 0/4
Infectious virus recovery at 24 mo <0.05 IUPM§ 22 ×106 resting  
CD4+ T cells
0/22
* PBMCs denotes peripheral-blood mononuclear cells.
† The limit of detection was 2.9 copies per 106 cells.
‡ The limit of detection was 23.3 copies per 106 cells.
§ No replication-competent HIV-1 was recovered.
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30 hours of age, along with a plasma viral load 
of 19,812 copies per milliliter detected at 31 
hours of age, is consistent with in utero infec-
tion. In two separate studies, the median viral 
loads at birth in infants who had been infected 
in utero were 10,800 copies per milliliter23 and 
26,940 copies per milliliter,24 as compared with 
undetectable levels in infants who were infected 
peripartum.
We believe that infection with replicating vi-
rus was likely, given the sequential detection of 
RNA in three serial blood samples obtained dur-
ing the first few weeks of life while the infant 
was receiving combination ART with reverse-
transcriptase inhibitors. The biphasic decline in 
viremia after the initiation of ART, with the 
rapid clearance (steep decline) of short-lived vi-
rus-producing cells (e.g., activated CD4+ T cells), 
followed by a slower decline, is consistent with 
the inhibition of active infection rather than 
with the clearance of passively transferred HIV-
1–infected maternal cells without infection of 
the infant’s cells. With these findings, the infant 
met the standard diagnostic criteria for HIV-1 
infection (most likely acquired in utero) as well 
as the criteria for initiation of ART and for par-
ticipation in clinical trials sponsored by the 
National Institutes of Health.22-25
We evaluated whether maternal–fetal blood 
transfusion could account for the detection of 
HIV-1 nucleic acid in the infant. An initial plas-
ma viral load of approximately 20,000 copies per 
milliliter in a 2.5-kg neonate is equivalent to a 
total body count of 5 million HIV-1 RNA copies 
or approximately 2.5 million virions. Such a re-
sult would have required the transfer of ap-
proximately 2 liters of maternal blood into this 
infant (whose total blood volume is only 250 ml). 
Likewise, the possibility that persistent detection 
of HIV-1 RNA during the first 3 weeks of life 
represented the passive transfer of virions from 
maternal blood is not consistent with the early-
infection events associated with postexposure 
prophylaxis in maternal–fetal transmission or 
neonatal HIV-1 infection, considering that the 
half-life of virions is 1 to 2 hours at most. Thus, 
the repeated detection of HIV-1 RNA in plasma 
through the infant’s first 19 days of life, while 
the infant was receiving ART, shows that there 
were virus-producing cells in the infant.
It is also conceivable that maternal microchi-
merism could have resulted in the detection of 
HIV-1 nucleic acid in the infant. Microchimerism 
has been detected in infants born to HIV-posi-
tive women but has not been associated with an 
increased risk of HIV-1 transmission.26 Although 
we were not able to directly assess maternal cells 
in the infant’s circulation, transfused maternal 
cells at the levels reported previously (0.3 to 
0.6% of neonatal cells26) are not likely to have 
resulted in the levels of plasma HIV-1 RNA that 
were detected shortly after birth in this infant.
A curious finding in this infant is the persis-
tence of traces of HIV-1 nucleic acid. The traces 
of viral nucleic acid may represent the persis-
tence of replication-defective genomes or false 
positive signals at the threshold of detection of 
the assays, as was recently reported for the Berlin 
Patient.27 Attempts to amplify HIV-1 from infant 
samples obtained for viral sequencing at 24 and 
26 months of age were unsuccessful, as were 
efforts to locate the screening samples obtained 
when the infant was a newborn to perform viral 
sequencing. The latter situation also precluded 
linkage analysis to maternal viral variants, which 
represents a limitation of this case report.
ART that is initiated between 1 and 3 months 
of age has been shown to modify HIV-1 persis-
tence in that infants who receive early treatment 
are often HIV-1 seronegative and do not have 
circulating viremia while they are receiving ART, 
but viral rebound has been observed when ART 
is discontinued.28-30 Approximately 5 to 10% of 
adults who receive early ART have sustained 
control of HIV-1 replication after the discontinu-
ation of therapy, although evidence for ongoing 
HIV-1 infection remains.31,32 The current case 
differs from those described in children29 and 
adults32 who receive early treatment in that cir-
culating proviral HIV-1 DNA and plasma HIV-1 
RNA were only intermittently detected at levels 
just above the limits of detection of the assays, 
replication-competent virus could not be recov-
ered, and the child remains HIV-1 seronegative 
even though ART was discontinued. This situa-
tion closely mimics the virologic and immuno-
logic biomarkers of the Berlin Patient at 5 years 
of follow-up.27
Viral and host factors could have contributed 
to the reported outcome in this child. The ma-
ternal HIV-1 RNA levels were relatively low at 
delivery, although fully replication-competent 
virus, with replication kinetics that were similar 
to a laboratory strain, was readily cultured from 
maternal cells 26 months post partum, from a 
blood sample showing a plasma viral load of 
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nearly 7000 copies per milliliter (Fig. S2 in the 
Supplementary Appendix). Although neither the 
mother nor the infant had HLA class I alleles 
that have been associated with control of HIV-1 
infection,33 it is possible that strong maternal im-
mune responses or other unknown host factors 
were responsible for the relatively low viral load 
seen in the mother, although maternal samples 
were not available for additional testing. The child 
remains in care, and at the age of 36 months, at 
least 18 months after the cessation of ART, the 
child has no detectable level of HIV-1 RNA.
This case suggests that very early ART may 
interfere with either the quantities or qualities of 
persistent reservoirs of replication-competent vi-
rus. Antiretroviral prophylaxis is routinely recom-
mended for infants who have been exposed to 
HIV-1, with multidrug regimens recommended 
in high-risk cases. Furthermore, the initiation of 
ART in infected infants markedly reduces HIV-
related mortality among infants25 and is recom-
mended by the World Health Organization. This 
global standard may facilitate planned proof-of-
concept studies of very early ART to modify per-
sistent HIV-1 infection in infants, with an aim 
toward sparing them a lifetime of therapy.
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